Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chloroquine Moves To Top of COVID-19 Clinical Trial List

Bayer, Novartis, Sanofi, Teva And Mylan Donating Antimalarial

Executive Summary

Many hopes for an effective coronavirus treatment are being pinned on chloroquine, not least those of President Trump, and pharma companies are supplying the antimalarial to the US at no cost for use in clinical trials.

You may also be interested in...



How Novartis Is Helping Staff Through COVID-19 Crisis

Speaking to Scrip, Steven Baert, chief people and organization officer at Novartis, said that a company’s response to coronavirus reveals its real identity and will shape its future.

Novartis CEO Backs Malaria Drug Against COVID-19

A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best placed to provide the quickest benefit.

FDA ‘Exception’ For Ipca’s Chloroquine/HCQ Amid Supply Plans From Others

Import alert hit-Ipca gets a temporary reprieve from US FDA for supplies of hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials in the spotlight as potential treatments for COVID-19. But with many firms committing to supplies/donations, analysts appear to be tempering enthusiasm for large windfall gains for the Indian firm.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141889

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel